Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma

Journal of Clinical Oncology

Volumn 12, Issue 3, 1994, Pages 454-466

  Gasparini, Giampietro ^b   Weidner, Noel ^a   Bevilacqua, Pierantonio ^c   Maluta, Sergio ^c   Palma, Paolo Dalla ^c   Caffo, Orazio ^c   Barbareschi, Mattia ^c   Boracchi, Patrizia ^c   Marubini, Ettore ^c   Pozza, Franco ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SAN BORTOLO HOSPITAL   (Italy)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN; PROTEIN P53;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER INVASION; CANCER RECURRENCE; CANCER SURVIVAL; HUMAN; MAJOR CLINICAL STUDY; MICROVASCULATURE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; TUMOR VASCULARIZATION; TUMOR VOLUME;

EID: 0028227085     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1994.12.3.454     Document Type: Article

References (69)

1. National Cancer Institute: Treatment alert issued for node-negative breast cancer. J Natl Cancer Inst 80:550-551, 1988
2. Glick JH: Meeting highlight: Adjuvant therapy for breast cancer. J Natl Cancer Inst 80:471-476, 1988
3. De Vita VT Jr: Breast cancer therapy: Exercising all our options. N Engl J Med 320:527-529, 1989 (editorial)
4. McGuire WL: Adjuvant therapy of node-negative breast cancer. Another point of view. J Natl Cancer Inst 80:1075-1076, 1988
5. Consensus Development Panel: Consensus statement: Treatment of early-stage breast cancer. J Natl Cancer Inst Monogr 11:1-5, 1992
6. Gasparini G, Pozza F, Harris AL: Evaluating the potential usefulness of new prognostic and predictive indicators in node-negative breast cancer patients. J Natl Cancer Inst 85:1206-1219, 1993
7. Osborne CK: Prognostic factors for breast cancer: Have they met their promise? J Clin Oncol 10:679-682, 1992 (editorial)
8. Henderson IC: Breast cancer therapy. The price of success. N Engl J Med 326:1774-1775, 1992 (editorial)
9. Fisher B, Redmond C, Dimitrov MV, et al: A randomized controlled trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-negative tumors. N Engl J Med 320:473-478, 1989
10. Mansour EG, Gray R, Shatila AH, et al: Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer: An intergroup study. N Engl J Med 320:485-490, 1989
11. Ludwig Breast Cancer Study Group: Prolonged disease-free survival after one course of peri-operative adjuvant chemotherapy for node-negative breast cancer. N Engl J Med 320:491-496, 1989
12. Fisher B, Costantino J, Redmond C, et al: A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-positive tumors. N Engl J Med 320:479-484, 1989
13. Bonadonna G, Valagussa P: Role of chemotherapy in stage I breast cancer, in De Vita VT Jr, Hellman S, Rosenberg SA (eds): Important Advances in Oncology 1989. Philadelphia, PA, Lippincott, 1989, pp 151-160
14. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339:1-15, 1992
15. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339:71-85, 1992
16. Weidner N, Folkman J, Pozza F, et al: Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 84:1875-1887, 1992
17. Bosari S, Lee AKC, De Lellis RA, et al: Microvessel quantitation and prognosis in invasive breast carcinoma. Hum Pathol 23:755-761, 1992
18. Horak E, Leek R, Klenk N, et al: Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 340:1120-1124, 1992
19. Toi M, Kashitani J, Tominaga T: Tumor angiogenesis is an independent prognostic indicator of primary breast carcinoma. Int J Cancer 55:341-374, 1993
20. Fox SB, Leek RD, Smith K, et al: Tumor angiogenesis in node-negative breast carcinomas - Relationship to epidermal growth factor receptor, estrogen receptor, and survival. Breast Cancer Res Treat 29:109-116, 1994
21. Visscher DW, Smilanetz S, Drozdowicz S, et al: Prognostic significance of image morphometric microvessel enumeration in breast carcinoma. Anal Quant Cytol Histol 15:88-92, 1993
22. Macchiarini P, Fontanini G, Hardin MJ, et al: Relation of neovasculature to metastasis of non-small-cell lung cancer. Lancet 340:145-146, 1992
23. Weidner N, Carroll PR, Flax J, et al: Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143:1-9, 1993
24. Bigler SA, Brawer MK, Deering RE: Neovascularization in carcinoma of the prostate: A quantitative morphometric study. Mod Pathol 5:50a, 1992 (abstr)
25. Wakui S, Furusato M, Itoh T, et al: Tumor angiogenesis in prostatic carcinoma with and without bone marrow metastasis: a morphometric study. J Pathol 168:257-262, 1992
26. Brawer MK, Deering RE, Brown M, et al: Predictors of pathologic stage in prostate carcinoma: The role of neovascularity. Cancer (in press)
27. Bigler SA, Brawer MK, Deering RE, et al: Vessel density in carcinoma of the prostate: comparing organ confined tumors with stage D tumors. Mod Pathol 6:56a, 1993 (abstr)
28. Gasparini G, Weidner N, Maluta S, et al: Intratumoral microvessel density and p53 protein: Correlation with metastasis in head and neck squamous cell carcinoma. Int J Cancer 55:739-744, 1993
29. Folkman J, Watson K, Ingber D, et al: Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339:58-61, 1989
30. Hart IR, Saini A: Biology of tumor metastasis. Lancet 339:1453-1457, 1992
31. Page DL, Dupont WD: Breast cancer angio-histogenesis: Through a narrow window. J Natl Cancer Inst 84:1850-1851, 1992 (editorial)
32. Thor AD, Moore DH II, Edgerton SM, et al: Accumulation of p53 tumor suppressor gene protein: An independent marker of prognosis in breast cancers. J Natl Cancer Inst 84:845-855, 1992
33. Isola J, Visakorpi T, Holli K, et al: Association of over expression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst 84:1109-1114, 1992
34. Allred DC, Clark GM, Elledge R, et al: Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 85:200-206, 1993
35. Silvestrini R, Benini E, Daidone MG, et al: p53 as an independent prognostic marker in lymph node-negative breast cancer patients. J Natl Cancer Inst 85:965-970, 1993
36. Veronesi U, Saccozzi R, Del Vecchio M, et al: Comparing radical mastectomy with quadrantectomy, axillary dissection and radiotherapy in patients with small cancers of the breast. N Engl J Med 305:6-11, 1981
37. Fisher ER, Gregorio RM, Fisher B: The pathology of invasive breast cancer. A syllabus derived from findings of the National Surgical Adjuvant Breast Project (protocol no. 4). Cancer 36:1-85, 1975
38. Bloom HG, Richardson WW: Histological grading and prognosis. Br J Cancer 11:359-377, 1957
39. Page DL, Anderson TJ: Vessel invasion, in Page DL, Anderson TJ (eds): Diagnostic Histopathology of the Breast. Edinburgh, UK, Churchill Livingstone. 1987, pp 283-284
40. Lee AKC, DeLellis RA, Silverman ML, et al: Prognostic significance of peritumoral lymphatic and blood vessel invasion in node-negative carcinoma of the breast. J Clin Oncol 8:1457-1465, 1990
41. Andersen J, Orntoft TF, Poulsen HS: Immunohistochemical demonstration of estrogen receptors (ER) in formalin-fixed paraffinembedded human breast cancer tissue by use of a monoclonal antibody to ER. J Histochem Cytochem 36:1553-1560, 1988
42. Bevilacqua P, Pea M, Gasparini G: Immunocytochemical detection of progesterone receptor by monoclonal KD-68 antibody in operable breast cancer: Correlations with biochemical assay, pathological features and cell proliferative rate. Eur J Cancer Clin Oncol 25:1595-1602, 1989
43. Parums DV, Cordell JL, Micklem K, et al: JC70: A new monoclonal antibody that detects vascular endothelium associated antigen on routinely processed tissue sections. J Clin Pathol 43:752-757, 1990
44. Weidner N, Semple JP, Welch WR, et al: Tumor angiogenesis and metastasis - Correlation in invasive breast carcinoma. N Engl J Med 324:1-8, 1991
45. Barbareschi M, Girlando S, Mavin FA, et al: Tumor suppressor gene products, proliferation and differentiation markers expression in lung neuroendocrine neoplasms. J Pathol 166:343-350, 1992
46. Gullick WJ, Berger MS, Bennet PLP, et al: Expression of the c-erbB2 protein in normal and transformed cells. Int J Cancer 40:246-254, 1987
47. Gasparini G, Gullick WJ, Bevilacqua P, et al: Human breast cancer: Prognostic significance of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features. J Clin Oncol 10:686-695, 1992
48. Wright C, Angus B, Nicholson S, et al: Expression of c-erbB2 oncoprotein: A prognostic indicator in human breast cancer. Cancer Res 49:2087-2090, 1989
49. Bennet S: Log logistic regression models for survival data. Appl Stat 32:165-171, 1983
50. Gray R: A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141-1154, 1988
51. Tandon AK, Clark GM, Chamnes GC, et al: Cathepsin D and prognosis in breast cancer. N Engl J Med 322:297-302, 1990
52. Liotta LA, Stetler-Stevenson G: Tumor invasion and metastasis: An imbalance of positive and negative regulation. Cancer Res 51:5054-5059, 1991 (suppl)
53. Gospodarowicz D, Thakral KK: Production of a corpus luteum angiogenic factor responsible for proliferation of capillaries and neovascularization of the corpus luteum. Proc Natl Acad Sci USA 75:847-851, 1978
54. Folkman J, Shing Y: Angiogenesis. J Biol Chem 267:10931-10934, 1992
55. Folkman J, Klagsbrum M: Angiogenic factors. Science 235:442-447, 1987
56. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82:4-6, 1990
57. Gould VE, Linnoila L, Memoli VA, et al: Neuroendocrine components of the bronchopulmonary tract: Hyperplasias, dysplasias, and neoplasms. Lab Invest 49:519-537, 1983
58. Allred DC, Clark GM, Tandon AK, et al: HER-2/neu in node negative breast cancer: Prognostic importance of the over expression influenced by the presence of in situ carcinoma. J Clin Oncol 10:599-605, 1992
59. Weinberg RA: Tumor suppressor genes. Science 254:1138-1146, 1991
60. Chen PL, Chen Y, Bookstein R, et al: Genetic mechanisms of tumor suppression by the human p53 gene. Science 250:1576-1579, 1990
61. Nigro JM, Baker SJ, Preisinger AC: Mutations in the p53 gene occur in diverse human tumor types. Nature 342:705-706, 1989
62. Halevy O, Michalowitz D, Oren M: Different tumor-derived p53 mutants exhibit distinct biological activities. Science 250:113-116, 1990
63. Clemente CG, Boracchi P, Andreola S, et al: Peritumoral lymphatic invasion in patients with node-negative mammary duct carcinoma. Cancer 69:1390-1403, 1992
64. Van Hoef MEHM, Knox WF, Dhesi SS, et al: Assessment of tumor vascularity as a prognostic factor in lymph node negative invasive breast cancer. Eur J Cancer 29A:1141-1145, 1993
65. Hall NR, Fish DE, Hunt N, et al: Is the relationship between angiogenesis and metastasis in breast cancer real? Surg Oncol 1:223-229, 1992
66. Ingber D, Fujita T, Kishimoto S, et al: Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth. Nature 348:555-557, 1990
67. Toi M, Yamamoto Y, Imazawa T, et al: Antitumor effect of the angiogenesis inhibitor AGM-1470 and its combination effect with tamoxifen in DMBA induced mammary tumors in rats. Int J Oncol 3:525-528, 1993
68. Lippman ME: The development of biological therapies for breast cancer. Science 259:631-632, 1993
69. Gasparini G, Harris AL: Does an improved control of tumour growth require an anti-cancer therapy targeting both neoplastic and intratumoral endothelial cells? Eur J Cancer (in press)